Company: LENZ
Filing Date: 2025-03-19
Form Type: 10-K
Source: 0001815776-25-000019
Chunk: 154

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-03-19
Form: 10-K
Item: Item 10
Chunk 154
---
 compensation earned for service on our board of directors during the year ended December 31, 2024 by non-employee directors. Mr. Schimmelpennink did not receive any additional compensation for his service as a director in 2024. Mr. Schimmelpennink's compensation as a named executive officer, and Ms Drapkin's compensation received as a non-employee director since the closing of the Merger, is set forth below under “— Summary Compensation Table.”

NameFees earned or paid in cash ($)Option awards ($)(1)All other compensation ($)Total ($)Jeff George(2)62,418 333,804 — 396,222 Frederic Guerard(3)46,423 333,804 — 380,227 James McCollum(4)31,209 333,804 — 365,013 Shelley Thunen(5)47,593 333,804 — 381,397 Zach Scheiner(6)40,962 333,804 — 374,766 Abraham Bassan(7)11,250 — — 11,250 Jerel Davis(7)11,625 — — 11,625 Kristin M. Hege(7)11,250 — — 11,250 Joseph Jimenez(7)11,625 — — 11,625 Perry Karsen(7)19,500 — — 19,500 Matthew Porteus(7)10,000 — 17,500 (8)27,500 Carlo Rizzuto(7)11,250 — — 11,250 Smital Shah(7)12,500 — — 12,500 Jo Viney(7)11,250 — — 11,250 

__________________

(1)In accordance with SEC rules, this column reflects the aggregate grant date fair value of the stock option awards granted during 2024, computed in accordance with FASB ASC Topic 718, Compensation—Stock Compensation. These amounts do not reflect the actual economic value that will be realized by the director upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options.

(2)As of December 31, 2024, Mr. George holds